文献速递免疫规划卫生政策与健康促进

2021年犹他州新冠疫苗接种后死亡风险评估

Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
PubMed 文献 · Vaccine · 2023-04-05

研究将犹他州免疫登记中2020年12月18日至2021年12月31日接种新冠疫苗者与2021年生命统计死亡记录匹配,按时间更新的一剂、两剂或≥三剂分组,分析接种后44周内粗死亡率及死因。结果显示接种后44周死亡率趋势未提示与新冠疫苗接种相关的死亡增加,支持疫苗安全性。

要点

  • 共识别2,072,908名至少接种一剂新冠疫苗者,其中10,997人于2021年死亡。
  • 接种第一或第二剂后四周内全因死亡率低,随后趋于稳定。
  • ≥三剂组因样本量小无法分析,但趋势相似。

核心结论

  • 接种新冠疫苗后44周内死亡率趋势未显示与疫苗接种相关的死亡增加,支持新冠疫苗安全性。

研究设计与样本

  • 将犹他州免疫登记中2020年12月18日至2021年12月31日有新冠疫苗接种记录者与犹他州2021年生命统计死亡记录匹配。
  • 接种者按时间更新指标分为接种一剂、两剂或≥三剂新冠疫苗。
  • 分析最近一次接种后44周内,按两周间隔分剂次组的全因粗死亡率,以及新冠与非新冠死因。

主要发现

  • 共识别2,072,908名至少接种一剂新冠疫苗者,其中10,997人于2021年死亡。
  • 全部接种人群中仅17.5%年龄≥65岁,而死亡者中80.9%年龄>65岁。
  • 接种第一或第二剂后四周内全因死亡率低,随后在评估期剩余时间趋于稳定,一剂和两剂组每两周平均死亡数分别为33.0和39.0例/10万人。
  • 两剂接种者中观察到典型的死亡季节性变化。
  • ≥三剂组因样本量小无法分析,但趋势相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • ≥三剂组因样本量小无法分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In order to evaluate trends in death after COVID-19 vaccination we analyzed the timing of death relative to vaccination date and the causes of death in vaccinated Utahns in 2021. METHODS: We matched people in the Utah immunization registry with documented COVID-19 vaccinations between December 18, 2020 and December 31, 2021 to Utah's 2021 vital statistics death records. Vaccinated people were categorized as having one, two, or ≥ three COVID-19 vaccine doses in a time-updated metric. We examined crude mortality rates by dosing groups in two-week intervals for all deaths, and by COVID-19 versus non-COVID-19 causes, within the 44 weeks following receipt of the most recent vaccine. RESULTS: We identified 2,072,908 individuals who received at least one dose of COVID-19 vaccine of whom 10,997 died in 2021. Only 17.5 % of the total vaccinated population was age 65+, while 80.9 % of those who died were over 65. In the four weeks following the first or second vaccination, all-cause mortality was low and then stabilized for the remainder of the evaluation period at a bi-weekly average of 33.0 and 39.0 deaths/100,000 people for one and two doses, respectively. Typical seasonal variation in death was observed among those with two doses. Small sample size precluded analysis of those with ≥ three doses, but trends were similar. CONCLUSIONS: Mortality rates in the 44 weeks following the COVID-19 vaccination did not show trends suggesting an increase in mortality related to COVID-19 vaccination, reinforcing the safety of COVID-19 vaccines. This represents an accessible approach for local evaluation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Payne JR, Bose S, Kubiak RW, et al. Evaluation of mortality risk after COVID-19 vaccination, Utah 2021. Vaccine. 2023. PMID: 37037710. doi:10.1016/j.vaccine.2023.03.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。